 |
- Provides solutions for analyzing brain atrophy and white matter hyperintensities, as well as monitoring side effects associated with Alzheimer’s disease treatments
- Secures a key reference site at a U.S. medical institution specializing in neurological disorders, accelerating product adoption across major healthcare institutions in North America
SEOUL, South Korea, Aug. 27, 2026 /PRNewswire/ — Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced today that it has signed a supply agreement with Elevate Clinic in the United States for Neurophet AQUA and Neurophet AQUA AD Plus.
Neurophet Supplies Neurophet AQUA and Neurophet AQUA AD Plus to Elevate Clinic in the U.S.
Based in Texas, Elevate Clinic is a medical institution specializing in neurological disorders and operates at six major cities in the state. In particular, the clinic is recognized for its integrated care system for patients with traumatic brain injury (TBI) and neurological disorders.
TBI is associated with a substantial patient population and significant burden on healthcare professionals in the United States, making the accurate detection of changes in brain volume and microhemorrhages resulting from brain injury important. Neurophet AQUA’s brain volumetry and atrophy analysis capabilities, along with Neurophet AQUA AD Plus’s microhemorrhage detection capabilities, can also be applied to brain imaging analysis for patients with TBI.
Neurophet AQUA is an AI-powered brain neurodegeneration imaging analysis software that rapidly performs quantitative analysis of patients’ brain magnetic resonance imaging (MRI) scans to assess brain atrophy and white matter hyperintensities (WMHs). It quantifies brain atrophy and WMHs associated with neurodegenerative diseases, including Alzheimer’s disease and vascular dementia, and provides customized analysis reports for clinicians.
Neurophet AQUA AD Plus is a comprehensive brain imaging analysis solution that provides the capabilities required throughout the prescription process for Alzheimer’s disease treatments. Using AI-powered brain MRI analysis, the software can automatically analyze the location and number of hypointense lesions associated with cerebral microhemorrhages and superficial siderosis, as well as hyperintense lesions associated with cerebral edema.
The supply agreement is significant as it establishes a foundation for the clinical use of Neurophet’s AI-powered brain imaging analysis solutions at a U.S. medical institution specializing in neurological disorders. Neurophet plans to expand clinical adoption across regional hospitals in the United States by leveraging Elevate Clinic as a reference site specializing in neurological disorders, thereby accelerating its business expansion in the U.S. market.
“Neurological disorders and TBI share commonalities from a brain imaging analysis perspective,” said a representative from Elevate Clinic. “We expect that Neurophet’s solutions will enable us to more precisely assess the brain condition of patients with TBI and support the delivery of more effective care.”
“By supplying Neurophet’s key products to Elevate Clinic in the United States, we are expanding our touchpoints with customers in the global market,” said Jake Junkil Been, Co-CEO of Neurophet. “We will continue to accelerate the adoption of our products across major medical institutions throughout North America.”
About Neurophet
Neurophet specializes in developing solutions for diagnosis support, treatment guides, and treatment devices targeting brain disorders based on cutting-edge artificial intelligence (AI) technology. The company was founded in 2016 by Co-CEOs Jake Junkil Been and Donghyeon Kim, who developed the next-generation neuro-navigation system.
Major products include brain MRI analysis software “Neurophet AQUA”, PET Image Quantitative Analysis Software “Neurophet SCALE PET”, Brain imaging treatment planning software for electric and magnetic brain stimulation “Neurophet tES/TMS LAB”, Alzheimer’s Disease treatment prescription and monitoring software “Neurophet AQUA AD” for tracking treatment efficacy and side effects, and Multiple Sclerosis image analysis software “Neurophet AQUA MS”.
Neurophet has set its top priority to helping patients suffering from brain disorders. Based on expertise in neuroscience, Neurophet will continue to challenge and grow to explore the human brain’s health and pioneer solutions for brain diseases with AI technology.
